Sivaprasad Sobha, Wong Tien Yin, Gardner Thomas W, Sun Jennifer K, Bressler Neil M
National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Institute of Ophthalmology, University College, London, UK.
Nat Rev Dis Primers. 2025 Aug 28;11(1):62. doi: 10.1038/s41572-025-00646-x.
Diabetic retinopathy is a complication of diabetes mellitus that is clinically characterized by changes in retinal microvasculature. Diabetic retinopathy is now better defined as diabetic retinal disease (DRD), as diabetes mellitus affects not only the retinal microvasculature but the whole retina, including neurons and glia. A global concerted effort to study preclinical and clinical signs of DRD and their association with visual acuity and patient-reported vision-related quality of life, and the integration of these features with systemic health and biochemical milieu in people with diabetes mellitus is underway. The Diabetic Retinopathy Clinical Research Retina Network trials and other researchers have provided substantial robust evidence on the current management of vision-threatening diabetic retinopathy that includes proliferative diabetic retinopathy and diabetic macular oedema. Progress is also being made to develop, evaluate and implement cost-effective strategies for personalized screening, treatment and monitoring, incorporating artificial intelligence as clinical decision support tools, where appropriate. In addition, novel therapies and modes of delivery are being evaluated to increase durability of interventions and improve affordability to improve vision-related quality of life and reduce the global burden of blindness owing to DRD.
糖尿病视网膜病变是糖尿病的一种并发症,其临床特征为视网膜微血管系统的改变。如今,糖尿病视网膜病变被更准确地定义为糖尿病性视网膜疾病(DRD),因为糖尿病不仅影响视网膜微血管系统,还影响整个视网膜,包括神经元和神经胶质细胞。目前正在全球范围内齐心协力研究DRD的临床前和临床体征及其与视力以及患者报告的视力相关生活质量的关联,并将这些特征与糖尿病患者的全身健康和生化环境相结合。糖尿病视网膜病变临床研究视网膜网络试验及其他研究人员已就目前对威胁视力的糖尿病视网膜病变(包括增殖性糖尿病视网膜病变和糖尿病性黄斑水肿)的管理提供了大量有力证据。在开发、评估和实施具有成本效益的个性化筛查、治疗和监测策略方面也取得了进展,在适当情况下将人工智能作为临床决策支持工具纳入其中。此外,正在评估新的治疗方法和给药方式,以提高干预措施的持久性并提高可承受性,从而改善视力相关生活质量并减轻因DRD导致的全球失明负担。